Nicholas J Taylor1, Nandita Mitra2, Lu Qian3, Marie-Françoise Avril4, D Timothy Bishop5, Brigitte Bressac-de Paillerets6, William Bruno7, Donato Calista8, Francisco Cuellar9, Anne E Cust10, Florence Demenais11, David E Elder12, Anne-Marie Gerdes13, Paola Ghiorzo7, Alisa M Goldstein14, Thais C Grazziotin15, Nelleke A Gruis16, Johan Hansson17, Mark Harland5, Nicholas K Hayward18, Marko Hocevar19, Veronica Höiom17, Elizabeth A Holland20, Christian Ingvar21, Maria Teresa Landi14, Gilles Landman22, Alejandra Larre-Borges23, Graham J Mann20, Eduardo Nagore24, Håkan Olsson21, Jane M Palmer18, Barbara Perić19, Dace Pjanova25, Antonia L Pritchard18, Susana Puig26, Helen Schmid20, Nienke van der Stoep27, Margaret A Tucker14, Karin A W Wadt13, Xiaohong R Yang14, Julia A Newton-Bishop5, Peter A Kanetsky28. 1. Department of Epidemiology and Biostatistics, Texas A&M University, College Station, Texas. 2. Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 4. Assistance Publique-Hôpitaux de Paris, Hôpital Cochin et Université Paris Descartes, Paris, France. 5. Section of Epidemiology and Biostatistics, Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom. 6. Gustave Roussy, Université Paris-Saclay, Département de Biopathologie and Institut National de la Santé et de la Recherche Médicale U1186, Villejuif, France. 7. Department of Internal Medicine and Medical Specialties, University of Genoa and Istituto de Ricovero e Cura a Carattere Scientifico AOU San Martino-IST, Genoa, Italy. 8. Dermatology Unit, Maurizio Bufalini Hospital, Cesena, Italy. 9. Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Institut de Investigacions Biomediques August Pi Sunyer, Universitat de Barcelona, Barcelona, Spain. 10. Sydney School of Public Health, The University of Sydney, Sydney, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia. 11. Institut National de la Santé et de la Recherche Médicale UMR-946, Genetic Variation and Human Disease Unit, Université Paris Diderot, Paris, France. 12. Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 13. Department of Clinical Genetics, University Hospital of Copenhagen, Copenhagen, Denmark. 14. Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. 15. Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil. 16. Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands. 17. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. 18. QIMR Berghofer Medical Research Institute, Herston, Australia. 19. Institute of Oncology Ljubljana, Zaloska, Ljubljana, Slovenia. 20. Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Westmead Institute for Medical Research, University of Sydney, Sydney, Australia. 21. Department of Clinical Sciences, Lund University Hospital Lund, Sweden; Department of Surgery, Lund University Hospital, Lund, Sweden. 22. Department of Pathology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. 23. Unidad de Lesiones Pigmentadas, Cátedra de Dermatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay. 24. Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain. 25. Latvian Biomedical Research and Study Centre, Riga, Latvia. 26. Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Institut de Investigacions Biomediques August Pi Sunyer, Universitat de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain. 27. Department of Clinical Genetics, Leiden University Medical Center Leiden, the Netherlands. 28. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. Electronic address: peter.kanetsky@moffitt.org.
Abstract
BACKGROUND: Although rare in the general population, highly penetrant germline mutations in CDKN2A are responsible for 5%-40% of melanoma cases reported in melanoma-prone families. We sought to determine whether MELPREDICT was generalizable to a global series of families with melanoma and whether performance improvements can be achieved. METHODS: In total, 2116 familial melanoma cases were ascertained by the international GenoMEL Consortium. We recapitulated the MELPREDICT model within our data (GenoMELPREDICT) to assess performance improvements by adding phenotypic risk factors and history of pancreatic cancer. We report areas under the curve (AUC) with 95% confidence intervals (CIs) along with net reclassification indices (NRIs) as performance metrics. RESULTS: MELPREDICT performed well (AUC 0.752, 95% CI 0.730-0.775), and GenoMELPREDICT performance was similar (AUC 0.748, 95% CI 0.726-0.771). Adding a reported history of pancreatic cancer yielded discriminatory improvement (P < .0001) in GenoMELPREDICT (AUC 0.772, 95% CI 0.750-0.793, NRI 0.40). Including phenotypic risk factors did not improve performance. CONCLUSION: The MELPREDICT model functioned well in a global data set of familial melanoma cases. Adding pancreatic cancer history improved model prediction. GenoMELPREDICT is a simple tool for predicting CDKN2A mutational status among melanoma patients from melanoma-prone families and can aid in directing these patients to receive genetic testing or cancer risk counseling.
BACKGROUND: Although rare in the general population, highly penetrant germline mutations in CDKN2A are responsible for 5%-40% of melanoma cases reported in melanoma-prone families. We sought to determine whether MELPREDICT was generalizable to a global series of families with melanoma and whether performance improvements can be achieved. METHODS: In total, 2116 familial melanoma cases were ascertained by the international GenoMEL Consortium. We recapitulated the MELPREDICT model within our data (GenoMELPREDICT) to assess performance improvements by adding phenotypic risk factors and history of pancreatic cancer. We report areas under the curve (AUC) with 95% confidence intervals (CIs) along with net reclassification indices (NRIs) as performance metrics. RESULTS: MELPREDICT performed well (AUC 0.752, 95% CI 0.730-0.775), and GenoMELPREDICT performance was similar (AUC 0.748, 95% CI 0.726-0.771). Adding a reported history of pancreatic cancer yielded discriminatory improvement (P < .0001) in GenoMELPREDICT (AUC 0.772, 95% CI 0.750-0.793, NRI 0.40). Including phenotypic risk factors did not improve performance. CONCLUSION: The MELPREDICT model functioned well in a global data set of familial melanoma cases. Adding pancreatic cancer history improved model prediction. GenoMELPREDICT is a simple tool for predicting CDKN2A mutational status among melanomapatients from melanoma-prone families and can aid in directing these patients to receive genetic testing or cancer risk counseling.
Authors: Scott R Florell; Kenneth M Boucher; Gilda Garibotti; John Astle; Richard Kerber; Geraldine Mineau; Charles Wiggins; R Dirk Noyes; Alexander Tsodikov; Lisa A Cannon-Albright; John J Zone; Wolfram E Samlowski; Sancy A Leachman Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: K B Niendorf; W Goggins; G Yang; K Y Tsai; M Shennan; D W Bell; A J Sober; D Hogg; H Tsao Journal: J Med Genet Date: 2005-09-16 Impact factor: 6.318
Authors: Alisa M Goldstein; May Chan; Mark Harland; Nicholas K Hayward; Florence Demenais; D Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarra; William Bruno; Donato Calista; Lisa A Cannon Albright; Valerie Chaudru; Agnes Chompret; Francisco Cuellar; David E Elder; Paola Ghiorzo; Elizabeth M Gillanders; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M MacKie; Veronica Magnusson; Graham J Mann; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson Journal: J Med Genet Date: 2006-08-11 Impact factor: 6.318
Authors: Colin B Begg; Irene Orlow; Amanda J Hummer; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Stephen B Gruber; Hoda Anton-Culver; Roberto Zanetti; Richard P Gallagher; Terence Dwyer; Timothy R Rebbeck; Nandita Mitra; Klaus Busam; Lynn From; Marianne Berwick Journal: J Natl Cancer Inst Date: 2005-10-19 Impact factor: 13.506
Authors: D Timothy Bishop; Florence Demenais; Alisa M Goldstein; Wilma Bergman; Julia Newton Bishop; Brigitte Bressac-de Paillerets; Agnès Chompret; Paola Ghiorzo; Nelleke Gruis; Johan Hansson; Mark Harland; Nicholas Hayward; Elizabeth A Holland; Graham J Mann; Michela Mantelli; Derek Nancarrow; Anton Platz; Margaret A Tucker Journal: J Natl Cancer Inst Date: 2002-06-19 Impact factor: 13.506
Authors: Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao Journal: J Am Acad Dermatol Date: 2009-10 Impact factor: 11.527
Authors: Noralane M Lindor; Rachel A Lindor; Carmel Apicella; James G Dowty; Amanda Ashley; Katherine Hunt; Betty A Mincey; Marcia Wilson; M Cathie Smith; John L Hopper Journal: Fam Cancer Date: 2007-07-17 Impact factor: 2.375
Authors: Mark Harland; Alisa M Goldstein; Kairen Kukalizch; Claire Taylor; David Hogg; Susana Puig; Celia Badenas; Nelleke Gruis; Jeanet ter Huurne; Wilma Bergman; Nicholas K Hayward; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Maria Teresa Landi; Giovanna Bianchi Scarra; Paola Ghiorzo; Peter A Kanetsky; David Elder; Graham J Mann; Elizabeth A Holland; D Timothy Bishop; Julia Newton Bishop Journal: Eur J Cancer Date: 2008-04-03 Impact factor: 9.162
Authors: W Bruno; B Dalmasso; M Barile; V Andreotti; L Elefanti; M Colombino; I Vanni; E Allavena; F Barbero; E Passoni; B Merelli; S Pellegrini; F Morgese; R Danesi; V Calò; V Bazan; A V D'Elia; C Molica; F Gensini; E Sala; V Uliana; P F Soma; M Genuardi; A Ballestrero; F Spagnolo; E Tanda; P Queirolo; M Mandalà; I Stanganelli; G Palmieri; C Menin; L Pastorino; P Ghiorzo Journal: ESMO Open Date: 2022-06-28